Clinical features of DLBCL subgroups with distinct phenotypes and expressions
. | CGH analysis . | . | . | . | Gene-expression profiling . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | CD5+ . | CD5−CD10+ . | CD5−CD10− . | Total . | ABC . | GCB . | Total . | |||||
| Age | ||||||||||||
| Median, y (range) | 62 (36-82) | 65 (48-89) | 57 (26-91) | 60 (26-91) | 67 (36-91) | 63 (38-89) | 64 (36-91) | |||||
| No. patients* | 36 | 19 | 44 | 99 | 28 | 18 | 46 | |||||
| Ann Arbor stage, no. patients (%) | ||||||||||||
| I-II | 5 (15) | 8 (42) | 17 (49) | 30 | 5 (20) | 7 (41) | 12 | |||||
| III-IV | 29 (85) | 11 (58) | 18 (51) | 58 | 20 (80) | 10 (59) | 30 | |||||
| Total* | 34 (100) | 19 (100) | 35 (100) | 88 | 25 (100) | 17 (100) | 42 | |||||
| Performance status, no. (%) | ||||||||||||
| 0-1 | 24 (71) | 16 (84) | 30 (97) | 70 | 16 (67) | 16 (100) | 32 | |||||
| 2 or more | 10 (29) | 3 (16) | 1 (3) | 14 | 8 (33) | 0 (0) | 8 | |||||
| Total* | 34 (100) | 19 (100) | 31 (100) | 84 | 24 (100) | 16 (100) | 40 | |||||
| LDH level, no. patients (%) | ||||||||||||
| Normal | 8 (24) | 12 (63) | 12 (38) | 32 | 6 (25) | 3 (19) | 9 | |||||
| High | 25 (76) | 7 (37) | 20 (62) | 52 | 18 (75) | 13 (81) | 31 | |||||
| Total* | 33 (100) | 19 (100) | 32 (100) | 84 | 24 (100) | 16 (100) | 40 | |||||
| No. of extranodal sites, no. patients (%) | ||||||||||||
| 1 or fewer | 24 (73) | 13 (68) | 25 (78) | 62 | 17 (71) | 13 (81) | 30 | |||||
| More than 1 | 9 (27) | 6 (32) | 7 (22) | 22 | 7 (29) | 3 (19) | 10 | |||||
| Total* | 33 (100) | 19 (100) | 32 (100) | 84 | 24 (100) | 16 (100) | 40 | |||||
| IPI index, no. patients (%) | ||||||||||||
| L/LI | 13 (38) | 9 (47) | 20 (65) | 42 | 5 (19) | 7 (41) | 12 | |||||
| H/HI | 21 (62) | 10 (53) | 11 (35) | 42 | 21 (81) | 10 (59) | 31 | |||||
| Total* | 34 (100) | 19 (100) | 31 (100) | 84 | 26 (100) | 17 (100) | 43 | |||||
. | CGH analysis . | . | . | . | Gene-expression profiling . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | CD5+ . | CD5−CD10+ . | CD5−CD10− . | Total . | ABC . | GCB . | Total . | |||||
| Age | ||||||||||||
| Median, y (range) | 62 (36-82) | 65 (48-89) | 57 (26-91) | 60 (26-91) | 67 (36-91) | 63 (38-89) | 64 (36-91) | |||||
| No. patients* | 36 | 19 | 44 | 99 | 28 | 18 | 46 | |||||
| Ann Arbor stage, no. patients (%) | ||||||||||||
| I-II | 5 (15) | 8 (42) | 17 (49) | 30 | 5 (20) | 7 (41) | 12 | |||||
| III-IV | 29 (85) | 11 (58) | 18 (51) | 58 | 20 (80) | 10 (59) | 30 | |||||
| Total* | 34 (100) | 19 (100) | 35 (100) | 88 | 25 (100) | 17 (100) | 42 | |||||
| Performance status, no. (%) | ||||||||||||
| 0-1 | 24 (71) | 16 (84) | 30 (97) | 70 | 16 (67) | 16 (100) | 32 | |||||
| 2 or more | 10 (29) | 3 (16) | 1 (3) | 14 | 8 (33) | 0 (0) | 8 | |||||
| Total* | 34 (100) | 19 (100) | 31 (100) | 84 | 24 (100) | 16 (100) | 40 | |||||
| LDH level, no. patients (%) | ||||||||||||
| Normal | 8 (24) | 12 (63) | 12 (38) | 32 | 6 (25) | 3 (19) | 9 | |||||
| High | 25 (76) | 7 (37) | 20 (62) | 52 | 18 (75) | 13 (81) | 31 | |||||
| Total* | 33 (100) | 19 (100) | 32 (100) | 84 | 24 (100) | 16 (100) | 40 | |||||
| No. of extranodal sites, no. patients (%) | ||||||||||||
| 1 or fewer | 24 (73) | 13 (68) | 25 (78) | 62 | 17 (71) | 13 (81) | 30 | |||||
| More than 1 | 9 (27) | 6 (32) | 7 (22) | 22 | 7 (29) | 3 (19) | 10 | |||||
| Total* | 33 (100) | 19 (100) | 32 (100) | 84 | 24 (100) | 16 (100) | 40 | |||||
| IPI index, no. patients (%) | ||||||||||||
| L/LI | 13 (38) | 9 (47) | 20 (65) | 42 | 5 (19) | 7 (41) | 12 | |||||
| H/HI | 21 (62) | 10 (53) | 11 (35) | 42 | 21 (81) | 10 (59) | 31 | |||||
| Total* | 34 (100) | 19 (100) | 31 (100) | 84 | 26 (100) | 17 (100) | 43 | |||||
Ninety-nine cases were subjected to array CGH analysis (left), and 46 of them to gene-expression profiling (right). L/LI, indicates low/low intermediate; H/HI, high/high intermediate.
Number of patients whose clinical data were available.